Please login to the form below

Not currently logged in
Email:
Password:

BMS sales up 14 per cent

Successful launches helped second-quarter sales for Bristol-Myers Squibb sales increase 14 per cent according to the pharmaceutical firm’s financial results

Successful launches helped second-quarter sales for Bristol-Myers Squibb (BMS) sales increase 14 per cent according to the pharmaceutical firm's financial results.

US-based BMS had revenue of $5.43bn for the quarter, compared to $4.77bn for the same period in 2010. This increase in revenue was helped by the launch of skin cancer drug Yervoy (ipilimumab) and Nulojix (belatacept), an immunosupressant to be used following a kidney transplant.

The company also saw sales for Plavix (clopidogrel bisulfate) increase 15 per cent to $1.87bn to remain BMS' best-selling product. The drug, which is co-marketed by Sanofi, was granted an extra six months of marketing exclusivity by the US Food and Drug Adminisration (FDA) in January 2011.

In its financial guidance for the year, the company expects high single-digit revenue growth, as well as extra expense in marketing, sales and administration. Advertising expenses are expected to decrease.

28th July 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Bedrock Healthcare Communications

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

Australian Flu and the dilemma of naming diseases
...
Wearables and Healthcare
What place do wearables have in affecting actual patient health outcomes and can they contribute to the NHS’s sustainability agenda? Or are they just the latest fad?...
What does a future-proof rep look like?
Businesses can no longer afford to push ahead with the traditional Key Account Management model....

Infographics